SelectQuote (SLQT) Shares Slide Further on Disappointing Earnings Amidst DOJ Scrutiny- Hagens Berman
SLQT Investors with Losses Encouraged to Contact the Firm
SAN FRANCISCO, May 29, 2025 /PRNewswire/ — SelectQuote Inc. (NYSE: SLQT) faced renewed investor pressure on Monday, May 12, 2025, as its shares tumbled another 12% following the release of quarterly results that fell short of earnings and revenue expectations. This decline compounds the over 19% drop experienced on May 1st after the U.S. Department of Justice (DOJ) announced a lawsuit alleging violations of the False Claims Act against the insurance brokerage and several major health insurers.
Hagens Berman is investigating potential violations of the U.S. securities laws and encourages SelectQuote investors who suffered substantial losses to submit your losses now. The firm also urges persons with knowledge who may be able to assist in the investigation to contact its attorneys.
Visit: www.hbsslaw.com/investor-fraud/slqtContact the Firm Now: SLQT@hbsslaw.com 844-916-0895
Earnings Miss Adds to Investor Woes
For the quarter ended March 2025, SelectQuote reported earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.04 per share. The company also posted revenues of $408.16 million, falling short of the Zacks Consensus Estimate of $417.01 million by 2.12%.
Mounting Troubles Weigh on Investor Confidence
This financial disappointment adds to the headwinds facing SelectQuote, which is already grappling with serious legal allegations. The DOJ lawsuit, unveiled on May 1st, accuses SelectQuote, along with other brokers and health insurance giants Aetna, Anthem, and Humana, of False Claims Act violations related to the marketing of Medicare Advantage (MA) plans.
The lawsuit alleges that, from 2016 through at least 2021, insurers paid significant sums to SelectQuote and other brokers for Medicare Advantage enrollments. The DOJ contends that, rather than providing unbiased guidance, SelectQuote and other brokers steered beneficiaries toward plans offering the highest commissions, potentially disregarding the suitability of those plans. The complaint further details allegations of incentivizing sales based on these commissions, establishing dedicated sales teams for specific high-commission plans, and instances of allegedly refusing to sell plans from insurers with lower commission structures. Discrimination against MA beneficiaries with disabilities is also alleged.
Hagens Berman's Investigation
The confluence of a weaker-than-anticipated earnings report and ongoing legal entanglements has amplified anxieties surrounding SelectQuote's financial stability and operational integrity. According to Reed Kathrein, the Hagens Berman partner spearheading an inquiry into the company, 'The recent earnings figures underscore our existing concerns about SelectQuote's alleged steering tactics in light of the DOJ's allegations.'
If you invested in SelectQuote and have substantial losses, or have knowledge that may assist the firm's investigation, submit your losses now »
If you'd like more information and answers to frequently asked questions about the SelectQuote investigation, read more »
Whistleblowers: Persons with non-public information regarding SelectQuote should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email SLQT@hbsslaw.com.
About Hagens BermanHagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
4 hours ago
- The Star
Investors to focus on geopolitics, US economic data this week
Traders work on the floor at the New York Stock Exchange (NYSE) in New York, US, on Monday, May 19, 2025.- Photographer: Michael Nagle/Bloomberg NEW YORK: Investors will focus on the Israel-Iran conflict and US economic data releases this week to assess the near-term outlook for stocks, as the S&P 500 hovers just below its February highs. The S&P 500 has rebounded sharply from its early-April sell-off, as tariff-related tensions have eased. However, the US benchmark index appears to be taking a breather at some 2.7% below its February closing high. The index has gone 27 trading sessions since coming within 5% of its February high but has not yet set a new record. With Israel and Iran trading missiles, escalating threats of a sweeping conflict in the Middle East sent oil prices sharply higher and led to caution in global markets. 'We're all waiting on pins and needles to see what happens with the Israel-Iran situation,' said Brian Jacobsen, chief economist at Annex Wealth Management. So far, the oil market has absorbed most of the impact from geopolitical turmoil, with equities relatively stable. Yet stock investors remain concerned that higher oil prices could stoke inflation and upset plans for interest rate cuts from the US Federal Reserve (Fed). Last Wednesday, the Fed held rates steady and the central bank's policymakers signalled borrowing costs are still likely to fall this year. But they estimated the overall pace of expected future rate cuts would be slower than they saw at their last meeting in March. They cited expectations that higher inflation would flow from President Donald Trump's tariff plans. 'The question is oil prices and what that does to inflation – which has implications for monetary policy and how long the Fed keeps rates 'meaningfully restrictive',' said Sonu Varghese, global macro strategist at financial services company Carson Group. The big near-term risk for equities, investors said, was the effects of the United States joining Israel's bombing campaign against arch-enemy Iran. The US joined Israel's bombardment of Iranian nuclear and missile sites last Saturday, as residents of Iran's capital Tehran streamed out of the city on the sixth day of the air assault. The White House had said last Thursday that Trump would decide on US action in the next two weeks. 'The US entry into the war or further escalation in the attacks between the two countries, that would give the S&P 500 and equity markets more reasons to react negatively,' said Damian McIntyre, head of multi-asset solutions at investment management company Federated Hermes in Pittsburgh. On the other hand, a de-escalation in Middle East tensions could prompt a relief rally for stocks. 'If both sides can kind of just slowly de-escalate, that would be positive for equity markets, positive for risk markets,' McIntyre said. 'Markets are taking a bit of a wait-and-see approach here,' he said. Still, any stock market pull-backs due to rising geopolitical tensions are likely to be fleeting, investors said. 'History says that usually military shocks are shallow and short-lived, and so until further notice, I think that's how Wall Street will react to this one,' Sam Stovall, chief investment strategist at CFRA Research, said. Investors will also parse a slew of incoming data releases, including US business activity and housing sales today, consumer confidence numbers tomorrow and the Personal Consumption Expenditures Price Index on Friday. US consumer confidence plunged in the past few months, with households fearing tariffs could prompt a recession and higher inflation. However, with inflation in check and the United States reaching a truce in its trade fight with China, investors expect to see a pickup in sentiment. 'Remember, the survey-based data all got crushed in the March, April, May time frame. My expectation is we're still going to see an improvement,' Mark Hackett, chief market strategist at Nationwide said. — Reuters
Malaysian Reserve
2 days ago
- Malaysian Reserve
Faruqi & Faruqi Reminds Organon Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Organon To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Organon between October 31, 2024 and April 30, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, June 20, 2025 /PRNewswire/ — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Organon & Co. ('Organon' or the 'Company') (NYSE: OGN) and reminds investors of the July 22, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See Defendants provided investors with material information concerning Organon's prioritization of its capital allocation strategy through regular, quarterly dividends. Defendants' statements included, among other things, reassurance that capital allocation through the aforementioned dividends was a '#1 capital allocation priority' and that Organon was committed to consistent deployment of capital. Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of the Company's priorities, particularly, related to capital allocation through quarterly dividends. Notably, Defendants concealed the high priority of Organon's debt reduction strategy following the Company's acquisition of Dermavant, resulting in a 70% decrease for the regular quarterly dividend. Such statements absent these material facts caused Plaintiff and other shareholders to purchase Organon's securities at artificially inflated prices. Investors and analysts again reacted promptly to Organon's revelations. The price of Organon's common stock declined dramatically. From a closing market price of $12.93 per share on April 30, 2025, Organon's stock price fell to $9.45 per share on May 1, 2025, a decline of more than 27% in the span of just a single day. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Organon's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Organon & Co. class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
Malaysian Reserve
2 days ago
- Malaysian Reserve
Faruqi & Faruqi Reminds Elevance Health Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 11, 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Elevance To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Elevance between April 18, 2024 and October 16, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, June 20, 2025 /PRNewswire/ — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Elevance Health, Inc. ('Elevance' or the 'Company') (NYSE: ELV) and reminds investors of the July 11, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that defendants represented to investors that they were closely monitoring cost trends associated with the redetermination process and that the premium rates Elevance was negotiating with states were sufficient to address the risk and cost profiles of those patients staying on Medicaid programs. While Defendants acknowledged that Medicaid expenses were rising, they repeatedly assured investors that this was adequately reflected in the Company's guidance for the year. The truth began to emerge on July 17, 2024, when the Company revealed that it was now 'expecting second-half utilization to increase in Medicaid.' In response to this disclosure, the price of Elevance common stock declined by $32.21 per share, or 5.8%. However, Defendants continued to make false, reassuring statements to investors concerning the extent of the cost increase and how that was accounted for in the Company's full year guidance. The truth was further revealed on October 17, 2024, when Elevance announced its financial results for the third quarter of 2024, revealing that the Company had missed consensus earnings per share ('EPS') expectations for the quarter by $1.33, or 13.7%, 'due to elevated medical costs in [its] Medicaid business.' Elevance further revealed that it was lowering EPS guidance for 2024 from $37.20 to $33.00, or 11.3%, as it expected these Medicaid issues to continue. These disclosures caused the price of Elevance common stock to decline by another $52.61 per share, or 10.6%. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Elevance's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Elevance Health class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
